Cevimeline
EVOXAC
What it isMuscarinic agonist favoring glandular M3 effects; xerostomia in Sjogren disease.
Why this oneIts salivary stimulation lasts longer than pilocarpine's, reducing the daily treatment burden.
What limits itSweating and GI upset commonly limit use. Avoid in uncontrolled asthma and narrow-angle glaucoma.
FDA-approved for
- dry mouth (Sjogren) (2000)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Dry mouth in Sjogren's syndrome | Adult | 30 mg TID | 30 mg TID | 30 mg TID (insufficient data above 30 mg tid) |
Renal Undefined
Hepatic Undefined
Contraindications
- Uncontrolled asthma
- Conditions where miosis is undesirable (acute iritis, narrow-angle/angle-closure glaucoma)
Adverse reactions
- Excessive sweating
- Nausea
- Rhinitis
- Diarrhea
- Excessive salivation
- Headache
- Sinusitis
- Upper respiratory infection
- Urinary tract infection
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskSweating; avoid in asthma and narrow-angle glaucoma
Cost, est. cash$10–$300/month
Generic entry2011
Classes and tags
Clinical profile
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Mechanism of action: Cevimeline ballicule
Open Cevimeline in the interactive console ↗
Memory aids: mascots and interaction avatars
light blue → muscarinic
saliva droplet characters
